12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

NewBridge Pharmaceuticals, Eisai sales and marketing update

Eisai and NewBridge partnered to commercialize Eisai's Halaven eribulin in the Middle East. The synthetic analog of...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >